EXEL vs PFE
EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | EXEL | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $59.02 | $27.82 | |
| Market cap | $14.6B | $158.6B | |
| P/E as of 2026-10-08 | 18.54 | 36.83 | EXEL lower |
| PEG as of 2026-10-08, 1-year EPS growth to FY2026 | 0.32 | n/a | |
| Net margin | +33.7% | +12.4% | EXEL higher |
| Operating margin FY2026, SEC XBRL | +37.6% | n/a | |
| ROE | +36.2% | +9.0% | EXEL higher |
| ROA | +27.5% | +3.7% | EXEL higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.74 | EXEL lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.2% | -0.2% | EXEL higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | -14.8% | EXEL higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.55 | 0.39 | |
| 1-year return as of 2026-10-08 close | +52.7% | +8.3% | EXEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.